← Back to patent-cliff list

Pradigastat

Tier C — Watch / trade

Pradigastat

Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:DGAT1

Indications (approved):Constipation, I型高脂蛋白血症, Hypertriglyceridaemia, Coronary artery lesion, Hepatitis C, Non-alcoholic steatohepatitis, Hepatic function decline, Renal impairment

Regional status

US
Phase II
2009-04-01
EU
Discontinued
2012-07-01
China
Phase II
2020-09-22
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield /
PRAD-001105640-07-1PRAD-0025927-18-4PRAD-003701232-66-8PRAD-004701232-67-9PRAD-005701232-68-0PRAD-00673183-34-3PRAD-007701232-69-1PRAD-008624-28-2PRAD-009956136-96-2PRAD-010106877-33-2PRAD-011956136-97-3API · Pradigastat
CodeCAS No.Intermediate
PRAD-001105640-07-14-(4-hydroxyphenyl)cyclohexan-1-one
PRAD-0025927-18-4Availablemethyl 2-(dimethoxyphosphoryl)acetate
PRAD-003701232-66-8methyl 2-(4-(4-hydroxyphenyl)cyclohexylidene)acetate
PRAD-004701232-67-9methyl 2-((1r,4r)-4-(4-hydroxyphenyl)cyclohexyl)acetate
PRAD-005701232-68-0methyl 2-((1r,4r)-4-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)cyclohexyl)acetate
PRAD-00673183-34-3Available4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
PRAD-007701232-69-1methyl 2-((1r,4r)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclohexyl)acetate
PRAD-008624-28-22,5-dibromopyridine
PRAD-009956136-96-2methyl 2-((1r,4r)-4-(4-(5-bromopyridin-2-yl)phenyl)cyclohexyl)acetate
PRAD-010106877-33-26-(trifluoromethyl)pyridin-3-amine
PRAD-011956136-97-3methyl 2-((1r,4r)-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexyl)acetate

Frequently asked questions

What are the approved indications of Pradigastat?

Approved indications include: Constipation, I型高脂蛋白血症, Hypertriglyceridaemia, Coronary artery lesion, Hepatitis C, Non-alcoholic steatohepatitis, Hepatic function decline, Renal impairment.

When does the Pradigastat patent expire?

No public expiry year is available for Pradigastat yet; this page updates once verified.

How many synthesis routes are recorded for Pradigastat?

1 synthesis routes are recorded; the shortest is 7 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Pradigastat intermediates?

2 intermediate CAS of Pradigastat are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Pradigastat intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21